(Q57295546)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30297911%20AND%20SRC:MED&resulttype=core&format=json

27 April 2020

title

Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30297911%20AND%20SRC:MED&resulttype=core&format=json

Alexander C.J. van Akkooi

27 April 2020

author

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30297911%20AND%20SRC:MED&resulttype=core&format=json

27 April 2020

Ton Schumacher

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30297911%20AND%20SRC:MED&resulttype=core&format=json

27 April 2020

2

Elisa A Rozeman

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30297911%20AND%20SRC:MED&resulttype=core&format=json

27 April 2020

1

Christian U Blank

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30297911%20AND%20SRC:MED&resulttype=core&format=json

27 April 2020

21

Daniel S Peeper

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30297911%20AND%20SRC:MED&resulttype=core&format=json

27 April 2020

22

John B A G Haanen

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30297911%20AND%20SRC:MED&resulttype=core&format=json

27 April 2020

author name string

Lorenzo F Fanchi

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30297911%20AND%20SRC:MED&resulttype=core&format=json

27 April 2020

Karolina Sikorska

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30297911%20AND%20SRC:MED&resulttype=core&format=json

27 April 2020

Bart van de Wiel

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30297911%20AND%20SRC:MED&resulttype=core&format=json

27 April 2020

Pia Kvistborg

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30297911%20AND%20SRC:MED&resulttype=core&format=json

27 April 2020

Oscar Krijgsman

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30297911%20AND%20SRC:MED&resulttype=core&format=json

27 April 2020

Marlous van den Braber

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30297911%20AND%20SRC:MED&resulttype=core&format=json

27 April 2020

Daisy Philips

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30297911%20AND%20SRC:MED&resulttype=core&format=json

27 April 2020

Johannes V van Thienen

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30297911%20AND%20SRC:MED&resulttype=core&format=json

27 April 2020

Henk A Mallo

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30297911%20AND%20SRC:MED&resulttype=core&format=json

27 April 2020

Sandra Adriaansz

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30297911%20AND%20SRC:MED&resulttype=core&format=json

27 April 2020

Sylvia Ter Meulen

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30297911%20AND%20SRC:MED&resulttype=core&format=json

27 April 2020

Loes M Pronk

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30297911%20AND%20SRC:MED&resulttype=core&format=json

27 April 2020

Lindsay G Grijpink-Ongering

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30297911%20AND%20SRC:MED&resulttype=core&format=json

27 April 2020

Annemarie Bruining

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30297911%20AND%20SRC:MED&resulttype=core&format=json

27 April 2020

Rachel M Gittelman

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30297911%20AND%20SRC:MED&resulttype=core&format=json

27 April 2020

Sarah Warren

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30297911%20AND%20SRC:MED&resulttype=core&format=json

27 April 2020

Harm van Tinteren

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30297911%20AND%20SRC:MED&resulttype=core&format=json

27 April 2020

Annegien Broeks

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30297911%20AND%20SRC:MED&resulttype=core&format=json

27 April 2020

language of work or name

English

0 references

publication date

8 October 2018

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30297911%20AND%20SRC:MED&resulttype=core&format=json

27 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30297911%20AND%20SRC:MED&resulttype=core&format=json

27 April 2020

volume

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30297911%20AND%20SRC:MED&resulttype=core&format=json

27 April 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30297911%20AND%20SRC:MED&resulttype=core&format=json

27 April 2020

page(s)

1655-1661

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30297911%20AND%20SRC:MED&resulttype=core&format=json

Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy

27 April 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0198-0

7 January 2021

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0198-0

7 January 2021

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0198-0

7 January 2021

Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease.

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0198-0

7 January 2021

Final version of 2009 AJCC melanoma staging and classification

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0198-0

7 January 2021

Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0198-0

7 January 2021

Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial.

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0198-0

7 January 2021

Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0198-0

7 January 2021

Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0198-0

7 January 2021

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0198-0

7 January 2021

Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial.

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0198-0

7 January 2021

Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies.

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0198-0

7 January 2021

CANCER IMMUNOLOGY. The "cancer immunogram".

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0198-0

7 January 2021

Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis.

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0198-0

7 January 2021

Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0198-0

7 January 2021

Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0198-0

7 January 2021

PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0198-0

7 January 2021

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0198-0

7 January 2021

Marking the axilla with radioactive iodine seeds (MARI procedure) may reduce the need for axillary dissection after neoadjuvant chemotherapy for breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0198-0

7 January 2021

Cellular immunocompetence in melanoma: effect of extent of disease and immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0198-0

7 January 2021

Short-term CTLA-4 blockade directly followed by PD-1 blockade in advanced melanoma patients: a single-center experience

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0198-0

7 January 2021

PD-1 Blockade Promotes Epitope Spreading in Anticancer CD8+ T Cell Responses by Preventing Fratricidal Death of Subdominant Clones To Relieve Immunodomination.

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0198-0

7 January 2021

Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response.

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0198-0

7 January 2021

PD-1 blockade induces responses by inhibiting adaptive immune resistance

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0198-0

7 January 2021

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0198-0

7 January 2021

Comprehensive assessment of T-cell receptor beta-chain diversity in alphabeta T cells

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0198-0

7 January 2021

Using synthetic templates to design an unbiased multiplex PCR assay.

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0198-0

7 January 2021

Ultra-sensitive detection of rare T cell clones.

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0198-0

7 January 2021

Design and use of conditional MHC class I ligands.

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0198-0

7 January 2021

10.1038/S41591-018-0198-0

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30297911%20AND%20SRC:MED&resulttype=core&format=json

27 April 2020

1 reference